When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.” Scorpion Therapeutics was born.
Read more https://www.fiercebiotech.com/biotech/scorpion-therapeutics-debuts-108m-to-put-sting-cancer